Matinas BioPharma (MTNB) Announces Quarterly Earnings Results

Matinas BioPharma (NYSEAMERICAN:MTNB) posted its earnings results on Tuesday. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.01), Fidelity Earnings reports.

Shares of NYSEAMERICAN:MTNB opened at $0.95 on Wednesday. Matinas BioPharma has a 52-week low of $0.32 and a 52-week high of $1.50.

MTNB has been the topic of several analyst reports. Roth Capital initiated coverage on shares of Matinas BioPharma in a research report on Monday, February 11th. They set a “buy” rating and a $4.75 target price on the stock. Zacks Investment Research raised shares of Matinas BioPharma from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Tuesday, April 16th.

TRADEMARK VIOLATION WARNING: This report was originally reported by Rockland Register and is the sole property of of Rockland Register. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://rocklandregister.com/2019/05/15/matinas-biopharma-mtnb-announces-quarterly-earnings-results.html.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Further Reading: Beige Book

Earnings History for Matinas BioPharma (NYSEAMERICAN:MTNB)

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.